Home » Stocks » Innovate Biopharmaceuticals

Innovate Biopharmaceuticals, Inc. (INNT)

May 4, 2020 - INNT merged into NMTR
Stock Price: $0.560 USD 0.000 (0.00%)
Updated May 1, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 23.14M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 41.33M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day May 1, 2020
Last Price $0.560
Previous Close $0.560
Change ($) 0.000
Change (%) 0.00%
Day's Open -
Day's Range 0.551 - 0.720
Day's Volume 1,547,785
52-Week Range 0.370 - 1.670

More Stats

Market Cap 23.14M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 41.33M
Float 63.85M
EPS (basic) n/a
EPS (diluted) -0.71
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.17M
Short Ratio 4.18
Short % of Float 2.70%
Beta -0.54
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.70
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share 0.00
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -193.21%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$10.00*
Low
10.0
Current: $0.560
High
10.0
Target: 10.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Innovate Biopharmaceuticals, Inc.
Country United States
Employees 8
CEO Sandeep Laumas

Stock Information

Ticker Symbol INNT
Stock Exchange NASDAQ
Unique Identifier NASDAQ: INNT

Description

9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products. The company is based in Raleigh, North Carolina.